An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies
Clinical Trial Grant
Awarded By
BeiGene USA, Inc.
Start Date
September 18, 2023
End Date
September 14, 2028
Awarded By
BeiGene USA, Inc.
Start Date
September 18, 2023
End Date
September 14, 2028